Thyroid Dysfunction and Cognitive Impairment: Neural Mechanisms and Neurofeedback‐Based Interventions Zhiqiang Ma, Yutong Liu, Mengyuan Chen, Mengyang Wang, Tao Liu Abstract ABSTRACTBackgroundThyroid dysfunction has emerged as a significant contributor to global public health challenges, with mounting evidence indicating its impact on cognitive function.MethodsThe current literature was synthesized to examine the association between thyroid dysfunction and cognitive impairments, the underlying neural mechanisms, and potential therapeutic approaches.ResultsA critical gap identified in this review is the incomplete understanding of the neural mechanisms underlying thyroid‐related cognitive decline, which hampers the development of targeted interventions.ConclusionNeurofeedback is examined as a potential therapeutic approach for cognitive rehabilitation, and future research directions are proposed to advance this field. This graphical abstract illustrates the Thyroid‐Brain‐Cognition model, summarizing the multi‐level mechanisms linking thyroid dysfunction to cognitive impairment, and emphasizes neurofeedback as a non‐invasive intervention targeting brain network modulation and neuroplasticity enhancement. [BRB3-16-e71817-g003.webp] Introduction Thyroid disorders represent a growing global health burden, with implications extending far beyond metabolic and cardiovascular complications. Recent epidemiological data highlight the increasing prevalence of thyroid dysfunction: the global age‐standardized incidence rate of thyroid cancer reached 2.914% in 2021, while in the United States, the age‐standardized prevalence of clinical thyroid dysfunction (hyperthyroidism and hypothyroidism) increased to 5.05% between 2015 and 2018, a 34.7% rise compared to 1999–2002 (Zhou et al. ; Zhang et al. ). This burden disproportionately affects older adults, with clinical hypothyroidism prevalence ranging from 0.2% to 5.7% and subclinical hypothyroidism rising sharply to 1.5%–12.5% among individuals over 65 years (Leng and Razvi ). Disruptions in thyroid hormone homeostasis are associated not only with metabolic, cardiovascular, and reproductive disorders (Teixeira et al. ; Jabbar et al. ; Krassas ), but also with significant neuropsychiatric consequences. Emerging evidence indicates that hyperthyroidism increases the risk of attention deficits and working memory impairments (Yudiarto et al. ), while hypothyroidism is linked to an 81% higher incidence of Alzheimer's disease. Alarmingly, patients undergoing thyroid hormone replacement therapy face a 3.3‐fold increased risk of dementia (Wieland et al. ). These findings underscore the urgent need for interdisciplinary research into thyroid‐associated cognitive impairment (TACI). Despite established associations between thyroid dysfunction and cognitive decline (Lazarus ), the field faces three major limitations: (1) Fragmented research scope: existing literature often focuses on isolated disease subtypes (e.g., Hashimoto's thyroiditis) or specific cognitive domains (e.g., executive function), failing to integrate multi‐level mechanisms such as molecular pathways, neuroimaging correlates, and neuroregulatory dynamics. (2) Absence of theoretical models: no existing theoretical model adequately explains how thyroid hormones dynamically modulate key brain networks (e.g., default mode network [DMN] hypoconnectivity in hypothyroidism), which hinders the development of targeted therapeutic strategies. (3) Lack of innovative interventions: novel neuroplasticity‐based approaches are largely absent from current TACI treatment frameworks, creating a gap between mechanistic understanding and clinical implementation. This gap persists despite accelerating advances in neuroendocrinology, leaving TACI without evidence‐based neurocognitive rehabilitation strategies. We first conduct a preliminary mapping of cognitive phenotypes across euthyroid, hyperthyroid, and hypothyroid states, identifying associated neural mechanisms such as hippocampal volume reduction and prefrontal cortex dysregulation. Subsequently, we integrate multimodal neuroimaging evidence to elucidate how thyroid hormones influence brain network remodeling. Specifically, we identify the decoupling of the default mode network (DMN) in memory deficits and the disruption of the executive control network (ECN) in attentional impairments. Finally, we propose a novel translational roadmap for neurofeedback‐based interventions. Utilizing real‐time neuroimaging techniques, we aim to modulate abnormal brain network activity and harness neuroplasticity for cognitive rehabilitation—a strategy that has not been previously explored in the context of TACI. This study introduces the first comprehensive “Thyroid–Brain–Cognition” triad model (see Figure ), identifying DMN/ECN connectivity patterns as potential early biomarkers and validating the efficacy of neurofeedback‐driven circuit remodeling. By integrating molecular mechanisms, neuroimaging biomarkers, and advanced neuromodulation techniques, we present a potential intervention framework that transitions from reactive hormone replacement to proactive cognitive restoration. Our findings pave the way for a transformative approach to reducing the neurocognitive burden of thyroid disorders, particularly among aging populations globally. Methods This systematic review was retrospectively registered in Prospero (ID: 1302279) and conducted in accordance with the PRISMA 2020 reporting guidelines. Predefined eligibility criteria, a dual‐stage screening procedure, and an auditable decision trail, including reasons for exclusion at each stage, were rigorously implemented to ensure methodological rigor and reproducibility. A comprehensive search strategy was implemented across five major electronic databases: PubMed, Embase, Scopus, Cochrane Library, and Google Scholar. The search spanned literature published from January 2000 to December 2025. The search syntax was structured around four conceptual domains, combined using Boolean operators: (1) thyroid‐cognitive interactions: (“Thyroid function AND cognitive function”); (2) hyperthyroidism‐related cognitive impairments: (“Hyperthyroidism AND cognitive impairment”); (3) hypothyroidism‐related memory disorders: (“Hypothyroidism AND cognitive impairment”); (4) intervention approaches: (“neurorehabilitation”). The initial search retrieved a total of 2497 non‐duplicate records. The selection process was documented using a PRISMA flowchart to ensure transparency and reproducibility. A three‐phase screening protocol was applied, with dual independent reviewers involved to minimize selection bias. (1) Phase 1: Deduplication and Language Filtering: Automated tools were used to remove duplicate entries and limit results to English‐language publications, eliminating 638 records. (2) Phase 2: Title and Abstract Screening: Titles and abstracts were evaluated against predefined methodological criteria. Studies such as animal models, conference abstracts, narrative reviews, and non‐primary research articles were excluded. (3) Phase 3: Full‐Text Evaluation: A total of 232 full‐text articles underwent critical appraisal using structured eligibility criteria: (a) human participants aged ≥18 years with confirmed euthyroid, hyperthyroid, or hypothyroid status; (b) use of validated cognitive assessment tools (e.g., MoCA, MMSE) or neuroimaging biomarkers; and (c) for interventional studies, inclusion of randomized controlled trials with active control arms. Exclusion criteria included case reports; underpowered cross‐sectional studies (n < 20); cohorts without baseline thyroid function data; and populations with comorbid neurological conditions (e.g., stroke, neurodegenerative disorders). Discrepancies between reviewers were resolved through consensus meetings or by consulting a third reviewer. Ultimately, 44 studies met all inclusion criteria and were included in the final analysis (see Figure ). Results Research Framework and Synthesis Strategy This review utilizes the PRISMA framework to synthesize current evidence on thyroid‐cognitive interactions across three clinically relevant dimensions: (1) cognitive correlates within the laboratory‐defined euthyroid range; (2) cognitive consequences of overt thyroid dysfunction; and (3) therapeutic efficacy of both conventional and emerging interventions. Systematic database searches yielded an initial pool of 2497 records. After a three‐stage screening process, 44 studies fulfilled the predefined inclusion criteria (32 observational studies; 12 interventional trials). This stratified approach enables a focused analysis of the pathophysiological continuum, ranging from subclinical hormone variations to overt dysfunction, while simultaneously identifying key gaps in the translation of mechanistic insights into neural pathways. Thyroid‐Cognitive Interplay: Mechanistic and Clinical Evidence Euthyroid Spectrum and Neurocognitive Vulnerability Thyroid hormones (THs) play a pivotal role in neurodevelopment, neuroplasticity, and neurotransmission, primarily regulated through the hypothalamic–pituitary–thyroid (HPT) axis (Brent ; Ortiga‐Carvalho et al. ). However, accumulating evidence indicates complex and often inconsistent associations between subtle variations in thyroid function within the clinically normal range and cognitive performance. For instance, a two‐sample Mendelian randomization study in individuals of European ancestry found that genetically predicted higher thyrotropin (TSH) levels within the euthyroid range were associated with reduced cognitive ability and prolonged reaction times (Yu and Shan ). In contrast, data from the prospective Rotterdam Study (n = 9446; mean age 65 years) showed that higher TSH levels within the normal range were independently linked to a lower risk of incident dementia, even after adjustment for cardiovascular risk factors (Chaker et al. ). Beyond linear associations, the Framingham Offspring Study (n = 1864 cognitively normal, euthyroid participants; mean follow‐up 12.7 years; 209 incident Alzheimer's disease [AD] cases, predominantly women) revealed a U‐shaped relationship. Women with serum TSH levels in the lowest (<1.0 mIU/L) and highest (>2.1 mIU/L) tertiles had more than double the risk of developing AD compared to those in the middle tertile (Tan et al. ). In contrast, a longitudinal study of 3401 euthyroid, cognitively intact individuals (with 145 incident dementia cases during follow‐up) reported no significant association between baseline TSH levels and dementia risk. However, men who later developed dementia exhibited higher baseline free thyroxine (FT4) levels (Yeap et al. ). Similarly, a study of 539 euthyroid US men aged ≥65 years found no correlation between baseline TSH or FT4 levels and measures of quality of life, mood, or cognitive function (Samuels et al. ). Hyperthyroidism and Cognitive Dysfunction Hyperthyroidism, characterized by excessive thyroid hormone (TH) secretion and symptoms such as weight loss, palpitations, and autonomic dysfunction, is increasingly associated with cognitive impairments, including attention deficits, memory decline, and reduced executive function (Jurado‐Flores et al. ). Notably, much of the research has focused on the link between hyperthyroidism and the risk of dementia. Using data from the Danish National Patient Registry (56,128 hyperthyroid patients vs. 224,512 matched controls) and the OPENTHYRO Registry (2688 hyperthyroid patients vs. 10,752 matched controls), a combined analysis revealed a significantly higher incidence of all‐cause dementia among hyperthyroid patients (Danish cohort: 4.9% vs. 3.6%; OPENTHYRO cohort: 7.1% vs. 4.4%, not statistically significant). Crucially, the pooled analysis demonstrated a 16% increased relative risk of all‐cause dementia for every 6‐month reduction in TSH duration, indicating a duration‐dependent elevation in dementia risk (Folkestad et al. ). Supporting these findings, the Atherosclerosis Risk in Communities Neurocognitive Study followed 12,481 participants (middle‐aged to elderly) for approximately 22 years. Although the majority had normal thyroid function, 3.4% exhibited overt hyperthyroidism (primarily exogenous). Compared with euthyroid controls, individuals with overt hyperthyroidism had a 40% higher risk of incident dementia (George et al. ). Collectively, these studies confirm a significant positive association between hyperthyroidism—particularly when prolonged—and an increased risk of dementia. Recently, a limited number of interventional studies have examined the effects of normalizing thyroid function. For instance, one month of antithyroid drug treatment (e.g., methimazole) partially restored functional connectivity between the prefrontal cortex and the posterior cingulate gyrus, suggesting that some neurocognitive impairments may be reversible with early intervention (Liu et al. ). However, several critical knowledge gaps remain: (1) the precise neural targets of therapeutic intervention are still undefined, which hinders the development of targeted therapies; (2) whether cognitive improvement can reciprocally facilitate thyroid function recovery remains unknown; and (3) there is a lack of comparative effectiveness data across different treatment modalities. Hypothyroidism and Cognitive Dysfunction Hypothyroidism, defined by insufficient thyroid hormone (TH) secretion and systemic manifestations such as fatigue, weight gain, and depression, is associated with inconsistent findings regarding domain‐specific cognitive deficits, particularly in working memory and executive function (Samuels ). A study comparing 14 untreated hypothyroid patients, 10 individuals with subjective cognitive complaints, and 10 healthy controls using standardized neuropsychological assessments found significant group differences only in verbal working memory (California Verbal Learning Test), with no differences observed in attention or non‐verbal tasks (Miller et al. ). Consistently, data from both the Danish National Patient Registry (111,565 hypothyroid patients vs. 446,260 matched controls) and the OPENTHYRO cohort confirmed a significantly increased risk of dementia among hypothyroid patients (Danish cohort: Risk Ratio 1.22, 95% CI 1.17–1.27). The OPENTHYRO data further showed a 12% increase in dementia risk for every 6 months of elevated TSH levels (Thvilum et al. ). Similarly, the Mexican Study on Aging and Dementia found that definite hypothyroidism (TSH > 4.8 mIU/L and FT4 < 13 pmol/L) was significantly associated with mild cognitive impairment as assessed by the Mini‐Mental State Examination (Juárez‐Cedillo et al. ). In contrast, a meta‐analysis examining the association between hypothyroidism and dementia report inconsistent conclusions. Some studies found no significant association after adjusting for vascular comorbidities (Ye et al. ), while others reported elevated risk across age groups and with persistent TSH elevation. Clinically, levothyroxine (LT4) replacement therapy indeed shows potential for partial cognitive recovery. For example, 6 months of LT4 treatment in subclinical hypothyroidism restored dorsolateral prefrontal cortex (DLPFC) activation and improved performance on the n‐back working memory task (Zhu et al. ). However, systematic evaluations of treatment efficacy that prioritize neural outcomes over biochemical normalization remain limited. Notably, residual cognitive impairments often persist even after biochemical euthyroidism is achieved, suggesting the possible involvement of non‐thyroid hormone‐related mechanisms (Quinque et al. ). The integration of neural biomarkers into clinical decision‐making remains limited, highlighting a significant translational gap. Summary of Previous Studies Current evidence indicates complex associations between thyroid dysfunction and cognitive impairment. However, accumulating research suggests that thyroid dysfunction, including both hyperthyroidism and hypothyroidism, is associated with an elevated risk of dementia. A key observation is the duration‐dependent nature of this association, whereby longer durations of thyroid dysfunction correlate with higher rates of dementia incidence. Nevertheless, a major limitation of prior studies is their primary focus on cognitive outcomes without directly examining the underlying neural deficits. As a result, the dynamic mechanisms by which thyroid hormone (TH) fluctuations affect neural network plasticity and contribute to cognitive decline remain poorly understood. This knowledge gap hinders the clinical differentiation between reversible functional impairments and irreversible structural damage, thereby limiting opportunities for timely and effective therapeutic intervention. Preliminary evidence indicates that short‐term antithyroid drug treatment may partially reverse cognitive deficits in hyperthyroidism, whereas persistent impairments observed in treated hypothyroidism suggest the involvement of non‐thyroid hormone‐related mechanisms. The emergence of novel interventions, such as neurofeedback, offers promising avenues for cognitive rehabilitation in individuals with thyroid disorders. Therefore, the following sections will review the neural basis of thyroid‐associated cognitive deficits (Section ) and evaluate the potential of neurofeedback as an intervention strategy (Section ). Neurological Mechanisms Underlying Thyroid Dysfunction and Cognitive Deficits Recently, resting‐state functional magnetic resonance imaging (rs‐fMRI) studies have revealed widespread functional connectivity (FC) abnormalities in hyperthyroidism. Patients with acute thyrotoxic myopathy exhibit significantly enhanced FC within the sensorimotor network and the left frontoparietal network—particularly involving regions such as the right superior temporal gyrus and the anterior/posterior cerebellar lobes—alongside reduced FC in areas including the occipital lobe and angular gyrus (Li et al. ). Furthermore, hyperthyroid patients demonstrate functional disconnection between the default mode network (DMN) and the salience network (SN), characterized by aberrant connectivity between the posterior cingulate cortex and anterior insula (Liu et al. ). These findings suggest that excess thyroid hormone (TH) may disrupt the dynamic balance of large‐scale brain networks essential for cognitive function. Abnormal hemodynamic responses in task‐relevant brain regions have also been implicated (Göbel et al. ). For instance, fMRI studies in both clinical and subclinical hypothyroidism consistently show reduced activation in the DLPFC and aberrant hippocampal connectivity during memory‐related tasks (Wheeler et al. ; Yin et al. ). Crucially, the strength of DLPFC‐hippocampal FC positively correlates with TH levels, and its disruption is hypothesized to underlie working memory deficits. TH deficiency appears to impair hippocampal neurogenesis and prefrontal synaptic plasticity, potentially through downregulation of brain‐derived neurotrophic factor (BDNF) and altered glutamate receptor expression (Vasilopoulou et al. ; Wheeler et al. ). Structural neuroimaging findings corroborate these functional alterations. MRI studies report reduced hippocampal volume and decreased prefrontal cortical gray matter density in hypothyroid patients (Cooke et al. ), consistent with observations of apoptosis in TH‐dependent memory circuits in rodent models. Additionally, THs modulate acetylcholinesterase (AChE) activity, specifically inhibiting the G1 (cytoplasmic) and G4 (membrane‐bound) AChE isoforms in the hippocampus and striatum (Vasilopoulou et al. ), which may disrupt cholinergic neurotransmission critical for learning and memory. Synthesizing current evidence (see Table ), thyroid dysfunction appears to adversely affect three core neurocognitive systems at the network level: (1) abnormal dynamic coupling between the default mode network (DMN) and dorsal attention network (DAN), potentially contributing to attention dysregulation; (2) weakened connectivity within the limbic‐prefrontal circuitry, impairing working memory encoding and emotional regulation; and (3) reorganization of cerebellar‐cortical circuits, affecting motor learning and coordination. Despite these insights, the precise neural pathways linking TH deficiency to specific cognitive impairments, particularly in human populations, remain poorly understood. Further targeted neuroimaging investigations are warranted. Neurofeedback Techniques: Potential Application for Thyroid‐Associated Cognitive Deficits Existing literature on interventions for thyroid‐associated cognitive dysfunction remains limited, primarily focusing on cognitive outcomes as secondary effects of standard thyroid treatment (Liu et al. ; Zhu et al. ). However, evidence indicating the involvement of non‐thyroid hormone mechanisms in persistent cognitive deficits (Quinque et al. ) highlights the potential value of adjunctive strategies that directly target neural function to improve patient prognosis and quality of life. Neurofeedback (NF), a non‐invasive intervention grounded in principles of neuroplasticity, enables closed‐loop modulation of specific brain regions through real‐time feedback of electroencephalogram (EEG) or hemodynamic activity (Thibault et al. ). It shows promise in the management of neurodegenerative conditions (Subramanian et al. ; Hohenfeld et al. ). For example, EEG‐based neurofeedback targeting the sensorimotor rhythm (SMR, 12–15 Hz) has significantly improved Montreal Cognitive Assessment (MoCA) scores in patients with mild cognitive impairment, potentially by enhancing thalamocortical inhibitory function (Marlats et al. ). Notably, the characteristic increase in theta band (4–7 Hz) power observed in hypothyroidism aligns with the frequency‐specific effects of SMR training, suggesting that EEG‐NF may offer a mechanism‐targeted approach for addressing thyroid‐related cognitive impairments (Wei et al. ). Personalized NF protocols demonstrate sustained efficacy. Interventions tailored to individual upper alpha frequency boundaries have shown lasting memory improvements for at least 1‐month post‐intervention in randomized controlled trials (Lavy et al. ). These advancements underscore the critical need to identify neural biomarkers specific to different thyroid disorders, such as aberrant functional connectivity patterns and abnormal spectral power signatures, to accurately localize dysfunctional brain circuits and optimize individualized NF parameters, including target region, frequency band, and reinforcement threshold (Molcho et al. ). Functional near‐infrared spectroscopy (fNIRS)‐based NF, which offers portability and moderate spatial resolution, holds considerable potential for cognitive rehabilitation. Research confirms that fNIRS‐NF targeting the left DLPFC significantly increases oxygenated hemoglobin concentration in patients with mild cognitive impairment, with neural changes strongly correlated with improvements in working memory (Lee et al. ). Similarly, a systematic review of 33 real‐time fMRI (rt‐fMRI)‐NF studies indicates that rt‐fMRI‐NF can enable learned modulation of specific brain signals, accompanied by measurable neural and behavioral changes (Wang et al. ). Collectively, these findings position neurofeedback technologies as a promising frontier for developing targeted interventions for thyroid‐associated cognitive impairments. Although NF holds considerable therapeutic promise, its current clinical implementation faces several potential limitations. First, accessibility and cost pose substantial barriers, particularly for real‐time fMRI‐based NF, which demands highly specialized imaging infrastructure, technical expertise, and sustained operational resources. Second, interindividual variability in treatment response is pronounced; this heterogeneity likely stems from differences in disease duration, residual neural plasticity, baseline cognitive function, and the presence or severity of comorbid affective symptoms. Third, a lack of standardized protocols severely impedes progress, existing studies diverge markedly in target brain regions, electrophysiological frequency bands, session dosage and total training duration, and selection of cognitive or neurophysiological outcome measures. Fourth, the majority of published NF trials in thyroid‐related cognitive impairment remain underpowered, with small sample sizes and limited follow‐up intervals, raising concerns regarding both long‐term clinical efficacy and population‐level generalizability. Collectively, these challenges underscore the urgent need for large‐scale, multicenter randomized controlled trials and the development of biomarker‐informed, disease‐specific neurofeedback protocols tailored to thyroid dysfunction. Currently, the evidence base for neurofeedback in thyroid disorders remains limited and largely exploratory; thus, clinical translation demands rigorous validation through adequately powered, prospective, biomarker‐stratified trials. Limitations A key limitation of this review is its retrospective registration with PROSPERO. To uphold methodological rigor and reporting transparency, future systematic reviews should register prospectively in accordance with established guidelines. Future Research Directions Future research should focus on three core dimensions to establish a comprehensive, multi‐level research framework for thyroid‐related cognitive impairment. The first dimension involves elucidating the underlying mechanisms and heterogeneity of these impairments. This requires deepening investigations into the neural substrates associated with thyroid‐related cognitive deficits, with particular attention to age‐ and sex‐related variations. For instance, the significantly higher hippocampal thyroid hormone receptor β (TRβ) density observed in women, along with sex‐specific associations with AD risk, characterized by a U‐shaped pattern in postmenopausal women versus a linear trend in men—underscores the need for sex‐stratified multi‐omics analyses (Tan et al. ). The second dimension focuses on developing tailored interventions, particularly through the design of neurofeedback (NF) systems specifically adapted for thyroid disorders. This approach necessitates real‐time feedback modalities capable of capturing the dynamic interactions between thyroid hormone (TH) fluctuation patterns (e.g., free thyroxine [FT4] circadian rhythm, thyroid‐stimulating hormone [TSH] pulsatility) and neuroplasticity biomarkers. Machine learning algorithms can be employed to develop predictive models of treatment response, enabling optimization of NF spatiotemporal parameters—such as training intervals aligned with TSH dynamics and region‐specific targets tailored to individual cognitive deficit profiles—and enhancing integration with levothyroxine (LT4) therapy. Furthermore, it is essential to consider the downstream cascading effects of cognitive impairment. The long‐term consequences of thyroid‐associated cognitive dysfunction on patients’ social functioning and neurodegenerative outcomes should be systematically evaluated. This could be achieved through the development of a multidimensional predictive model that integrates neuropsychological assessments, multiple biomarker clusters, and digital phenotypic monitoring. Such a model would allow quantification of how executive function deficits contribute to declines in daily living abilities. Particular emphasis should be placed on incorporating thyroid function fluctuation parameters into predictive models of progression from mild cognitive impairment to dementia, as well as on assessing the synergistic amplification effect of combined cognitive‐motor deficits on fall risk. Coordinated advancement across these research directions will facilitate progress along the entire translational spectrum, from basic mechanisms to clinical applications, thereby providing a robust scientific foundation for the development of precise prevention and treatment strategies for thyroid‐related cognitive impairment. Conclusion This review synthesizes current evidence demonstrating a complex, duration‐dependent association between thyroid dysfunction and cognitive impairment, particularly in episodic memory, working memory, and executive control, and identifies large‐scale brain network reorganization as a key neurobiological substrate. Empirical findings consistently indicate that both hyperthyroidism and hypothyroidism disrupt functional integrity within canonical neural circuits, resulting in deficits in domain‐specific cognition. Critically, such network‐level disturbances and associated cognitive impairments frequently persist despite restoration of euthyroid status through standard hormonal replacement therapy. The “Thyroid–Brain–Cognition” triadic model integrates these observations into a coherent, multilevel framework: it posits that chronic endocrine dysregulation drives maladaptive neuroplastic changes in large‐scale networks, which mediate downstream cognitive decline. The model further proposes that neuromodulatory strategies, such as neurofeedback, represent a mechanistically grounded, adjunctive approach to conventional endocrine management. Nevertheless, the existing evidence base for neurofeedback‐based interventions remains limited and largely hypothesis‐generating. Robust clinical implementation therefore hinges on validation through adequately powered, prospective, and protocol‐standardized trials. To advance precision cognitive rehabilitation in thyroid disorders, future research should prioritize longitudinal, multimodal studies that integrate dynamic thyroid hormone profiling, quantitative neuroimaging biomarkers, and standardized cognitive phenotyping, enabling patient stratification and hypothesis‐driven intervention development. Ethics Statement The authors have nothing to report.